Under fire for pricing and more, PhRMA boosts lobbying spend 30% in 2017

PhRMA increased its lobbying expenses by 29% in 2017, according to disclosure forms. (Pixabay)

As the drug industry took heat from Trump in 2017 for "getting away with murder," among other criticisms, its lobbyists were busy behind the scenes working with officials to protect it, according to lobbying disclosure forms. In all, the industry's biggest lobby group, PhRMA, boosted its spending by 29.6% last year.

PhRMA spent the most on lobbying—$7.98 million—in the first quarter, according to the disclosure documents. Its efforts ranged from patent issues, Bayh-Dole march-in rights, importation, Medicare price negotiations and more. 

The first quarter of 2017 was also when then President-elect Donald Trump blasted the industry for "getting away with murder" and for its influence in Washington.  

“Pharma has a lot of lobbies, lobbyists and a lot of power," he said at the time. "There is very little bidding on drugs.”

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Drug stocks fell immediately, but over time, industry concerns about government intervention on prices have eased.  

RELATED: Trump to pharma: You're 'getting away with murder,' and I'm the one to stop it 

Despite the tough talk, much of the Trump administration's actions on drug pricing have been focused around increasing competition through the FDA rather than on a larger regulatory overhaul. All told in 2017, PhRMA spent $25.43 million lobbying, according to its disclosure forms, compared to $19.62 million in 2016.  

In response to an intense focus on drug prices over the last several years, many drugmakers have committed to limiting their price increases, while the industry has also tried to shift the spotlight to growing rebates and discounts paid to payers.

Just this month, two biopharma CEOs offered contrasting perspectives on the pricing issue at the J.P. Morgan Healthcare Conference. Merck CEO Ken Frazier said he doesn't expect "any kind of significant jump" in pricing pressure from payers or public agencies, while Eli Lilly CEO David Ricks said the industry should get involved in moderating prices or it might face more pushback. 

With "people who are in power who understand that tricky balance, that fragile balance between reward for innovation and access," Ricks said it's important for the industry to act on ensuring affordability.

Suggested Articles

Rumor has it that several companies are in talks to buy Daiichi's over-the-counter drugs business, which could fetch $900 million.

When it comes to Invokana sales, J&J needs a way to stop the bleeding. And it just took a step closer to a new approval that could do just that.

Novartis last year said its forthcoming SMA gene therapy could be cost effective at up to $5 million. Now, its CEO says the price will be "far lower."